| Therapeutic | Enristomig |
| Target 1 | PDL1/CD274 |
| Heavy Chain 1 | EVQLLESGGGEVQPGGSLRLSCAASGGIFAIKPISWYRQAPGKQREWVSTTTSSGATNYAESVKGRFTISRDNAKNTLYLQMSSLRAEDTAVYYCNVFEYWGQGTLVTVKP |
| Light Chain 1 | na |
| 100% seqID Fv 1 Structure | None |
| 99% seqID Fv 1 Structure | None |
| 95-98% seqID Fv 1 Structure | None |
| Target 2 | TNFRSF9/CD137/4-1BB |
| Heavy Chain 2 | EVQLLESGGGEVQPGGSLRLSCAASGFSFSINAMGWYRQAPGKRREFVAAIESGRNTVYAESVKGRFTISRDNAKNTVYLQMSSLRAEDTAVYYCGLLKGNRVVSPSVAYWGQGTLVTVKP |
| Light Chain 2 | na |
| 100% seqID Fv 2 Structure | None |
| 99% seqID Fv 2 Structure | None |
| 95-98% seqID Fv 2 Structure | None |
Follow these links to our prediction tools:
| Format | Bispecific Single Domains (VH-VH'-G1(h-CH2-CH3) Dimer) |
| Isotype | G1;G1 |
| Highest Clinical Trial (Feb '25) | Phase-I |
| Estimated Status (Feb '25) | Discontinued |
| Recorded Developmental Technology | |
| INN Year Proposed | 2023 |
| INN Year Recommended | 2024 |
| Companies Involved | Elpiscience Biopharmaceuticals, Inhibrx |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Hodgkin's disease, Non-Hodgkin's lymphoma, Solid tumours, Non-small cell lung cancer, Oesophageal cancer, Squamous cell cancer |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
